Table 2 Overall summary of GT-30 TRAEs
TRAEsa (n = 27/36) | Grade 1/2 |
|---|---|
Injection-site reactions | |
Pain, erythema, pruritus or swelling | 15 (41.6%) |
Gastrointestinal | |
Gastroesophageal reflux | 2 (5.6%) |
Diarrhea | 1 (2.8%) |
Abdominal pain (upper) | 1 (2.8%) |
Nausea | 1 (2.8%) |
Dry mouth | 1 (2.8%) |
Skin | |
Rash | 4 (11.1%) |
Pruritus | 2 (5.6%) |
Dermatitis | 1 (2.8%) |
Alopecia | 1 (2.8%) |
Skin disorder | 1 (2.8%) |
Dry skin | 1 (2.8%) |
Endocrine | |
Hypothyroidism | 2 (5.6%) |
Musculoskeletal | |
Pain in extremities, musculoskeletal pain or stiffness | 3 (8.3%) |
Arthralgia | 1 (2.8%) |
Metabolism | |
Decreased appetite | 2 (5.6%) |
Hypophosphatemia | 1 (2.8%) |
Polydipsia | 1 (2.8%) |
General | |
Fatigue | 4 (11.1%) |
Pyrexia | 1 (2.8%) |
Chills | 1 (2.8%) |
Anemia | 1 (2.8%) |
Dysesthesia | 1 (2.8%) |
Lethargy | 1 (2.8%) |
Somnolence | 1 (2.8%) |
Infusion-related reaction | 1 (2.8%) |
Chest discomfort | 1 (2.8%) |
Hepatitis | 1 (2.8%) |
Elevated liver function test results | 1 (2.8%) |
Immune-related | |
Immune-mediated nephritis | 1 (2.8%) |
Pneumonitis | 1 (2.8%) |
ICI hepatitis | 1 (2.8%) |
Use of systemic steroids | 7 (19.4%) |
